A COMPARATIVE STUDY OF ORAL PSORALEN VS METHYLPREDNISOLONE WITH NARROW BAND UVB THERAPY IN VITILIGO
DOI:
https://doi.org/10.22159/ajpcr.2024v17i12.53085Keywords:
Vitiligo, Phototherapy, NB-UVB, Dermatological life quality index, Oral Psoralen, MethylprednisoloneAbstract
Objective: The efficacy and safety evaluation of oral Psoralen and of oral Methylprednisolone along with narrow-band ultraviolet B (NB-UVB). To observe the safety and efficacy of oral Psoralen in patients of Vitiligo. To observe the safety and efficacy of oral Methylprednisolone along with NB-UVB in patients of Vitiligo. To compare the safety and efficacy of oral Psoralen and oral Methylprednisolone along with NB-UVB during the study. To assess the dermatological life quality index (DLQI) in patients of Vitiligo before, during treatment, and after treatment.
Methodology: A randomized controlled trial was conducted involving 76 patients diagnosed with generalized vitiligo. Patients were randomly assigned to either Group A or Group B. Group A received oral psoralen (0.3–0.6 mg/kg) followed by Twice-weekly sessions of NB-UVB therapy along with methylprednisolone.
Results: As per the observations, the DLQI of the patients treated with the methylprednisolone with NB-UVB were showing better results as compared to the oral psoralen group.
Conclusion: Even though vitiligo does not pose a direct threat to a person’s physical or mental health, it does cause a great deal of suffering for those who suffer from it and their loved ones. Therefore, treatment is necessary. While there are a number of systemic and topical treatments for this condition, phototherapy – and particularly NB-UVB – is among the most effective and safest options.
Downloads
References
Bergqvist C, Ezzedine K. Vitiligo: A review. Dermatology. 2020 Mar 10;236(6):571-92. doi: 10.1159/000506103, PMID 32155629
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011 Sep 1;65(3):473-91. doi: 10.1016/j.jaad.2010.11.061, PMID 21839315
Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol. 1977 Jan 1;113(1):47- 52. doi: 10.1001/archderm.113.1.47, PMID 831622
Behl PN, Bhatia RK. 400 cases of vitiligo. A clinico-therapeutic analysis. Indian J Dermatol. 1972 Jan;17(2):51-6. PMID 5039893
Sehgal VN, Srivastava G. Vitiligo: Compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007 May 1;73(3):149-56. doi: 10.4103/0378-6323.32708, PMID 17558045
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012 Oct;51(10):1206-12. doi: 10.1111/j.1365-4632.2011.05377.x, PMID 22458952
Lee H, Lee MH, Lee DY, Kang HY, Kim KH, Choi GS, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J. 2015 May 5;56(3):719-25. doi: 10.3349/ymj.2015.56.3.719, PMID 25837178
Hann SK, Lee HJ. Segmental vitiligo: Clinical findings in 208 patients. J Am Acad Dermatol. 1996 Nov 1;35(5 Pt 1):671-4. doi: 10.1016/ s0190-9622(96)90718-5, PMID 8912558
Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998;38(5 Pt 1):647-66, quiz 667. doi: 10.1016/s0190-9622(98)70194-x, PMID 9591808
Oakley AM. Rapid repigmentation after depigmentation therapy: Vitiligo treated with monobenzyl ether of hydroquinone. Australas J Dermatol. 1996 May;37(2):96-8. doi: 10.1111/j.1440-0960.1996. tb01014.x, PMID 8687336
Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005 Jan 1;25;Suppl:63-8. doi: 10.1016/j. jaut.2005.10.001, PMID 16298511
D’Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME. Signaling pathways in melanogenesis. Int J Mol Sci. 2016 Jul 15;17(7):1144. doi: 10.3390/ijms17071144, PMID 27428965
Charkoudian LD, Ying GS, Pujari SS, Gangaputra S, Thorne JE, Foster CS, et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012 Apr 1;20(2):91- 9. doi: 10.3109/09273948.2011.646382, PMID 22409561
Garg N, Perry L, Deodhar A. Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids. Clin Rheumatol. 2014 Dec;33(12):1695-706. doi: 10.1007/s10067-014- 2572-8, PMID 24651914
Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun 1;50(6):859-66. doi: 10.1016/j.jaad.2003.09.014, PMID 15153885
Anabar TE, El-Domyati MM, Abdel-Aziz R, Mohammed, M. The efficacy of Narrow-Band ultraviolet-B Therapy on vitiligo patients. Minia J Med Res. 2020 Apr 1;31(2):277-9. doi: 10.21608/ mjmr.2022.221067
Khanna U, Khandpur S. What is new in narrow-band ultraviolet-B therapy for vitiligo? Indian Dermatol Online J. 2019 May 1;10(3):234- 43. doi: 10.4103/idoj.IDOJ_310_18, PMID 31149564
Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006 Feb;20(2):175-7. doi: 10.1111/j.1468- 3083.2006.01413.x, PMID 16441626
Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: Efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol. 2007 May 1;143(5):578- 84. doi: 10.1001/archderm.143.5.578, PMID 17519217
Published
How to Cite
Issue
Section
Copyright (c) 2024 Rahul Kumar Pal
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
